Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Patent
1995-09-22
1998-11-10
Minnifield, Nita
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
530364, 530806, 4242691, 4241841, 930210, C07K 100, C07K 1400, C07K 1700, A61K 39002
Patent
active
058345922
ABSTRACT:
Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.
REFERENCES:
Bixler et al, .COPYRGT.1987, In: Synthetic Vaccines Ed. Arnon. pp. 39-71.
Houghten 1986 Vaccines 86, pp. 21-25.
Bowie et al, 1990. Science, 247:1306-1310.
Skeiky et al., "A Recombinant Leishmania Antigen that Stimulates Human Peripheral Blood Mononuclear Cells to Express a Th1-Type Cytokine Profile and to Produce Interleukin 12," Journal of Experimental Medicine 181(4): 1527-1537, 1995.
Skeiky et al., "Proliferative and Cytokine Responses of Human PBMC to Cloned Leishmania Braziliensis Heat shock and Ribosomal Antigens,", Journal of Immunology 150(8 pt. 2): 93A, Abstract #517, 1993.
Shapira and Pedraza, "Sequence analysis and transcriptional activation of heat shock protein 83 of Leishmania mexicana amazonensis," Molecular and Biochemical Parasitology 42(2): 247-255, 1990.
De Andrade et al., "Recombinant Leishmania Hs90 and Hsp70 Are Recognized by Sera from Visceral Leishmaniasis Patients but Not Chagas' Disease Patients," Journal of Clinical Microbiology 30(2): 330-5, 1992.
Mougneau et al., "Expression Cloning of a Protective Leishmania Antigen, " Science 268: 563-566, 1995.
Campos-Neto et al, "Cloning and Expression of a Leishmania donovani Gene Instructed by a Peptide Isolated from Major Histocompatibility Complex Class II Molecules of Infected Macrophages," Journal of Experimental Medicine 182(5): 1423-1433, 1995.
EMBL Database Entry LDP23CSPR, Accession No. X86551, "L. donovani mRNA for 23 kDa cell surface protein," Apr. 26, 1995.
Pir2 Database, Accession No. S54162, "Leishmania donovani," Jul. 8, 1995.
Frommel et al., "Vaccine-Induced Immunity against Cutaneous Leishmaniasis in BALB/c Mice,"Infection and Immunity 56(4): 843-848, 1988.
Dillon et al., "Characterization of a Leishmania tropica antigen that detects immune reponses in Desert Storm viscerotropic leishmaniasis patients," Proc. Natl. Acad. Sci. USA 92: 7981-7985, 1995.
Campos-Neto Antonio
Dillon Davin C.
Reed Steven G.
Skeiky Yasir A. W.
Webb John R.
Corixa Corporation
Minnifield Nita
LandOfFree
Leishmania antigens for use in the therapy and diagnosis of Leis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leishmania antigens for use in the therapy and diagnosis of Leis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leishmania antigens for use in the therapy and diagnosis of Leis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1517843